Skip to main content

Liraglutide

No sources yet

An index of captured practitioner sources, not a completed evidence summary. Unchecked figures and empty sections are omitted. See the library review status.

Source summary generated November 6, 2026; this date does not indicate completed review.

Fat Loss

Brand names: Victoza, Saxenda

Track your own protocol free →

Quotes from three independent practitioners, with their sources. Research context only.

What it is and how it works

From the published literature on Liraglutide; the papers are listed at the end. Research summary, not a recommendation.

What it is

Liraglutide is a GLP-1 receptor agonist developed by Novo Nordisk: a copy of the human gut hormone GLP-1 (31 amino acids) with one amino-acid swap and a fatty-acid chain attached, which makes it bind to albumin in the blood and last long enough for once-daily injection. It was approved for type 2 diabetes as Victoza (EU 2009, US 2010) and, at a higher strength, for chronic weight management as Saxenda (US 2014). Generic liraglutide became available in the US in 2024.

How it works

Liraglutide binds the GLP-1 receptor, a sensor on pancreatic beta cells, the brain and the gut that normally responds to the hormone released after eating. It increased insulin release only when blood glucose was raised, lowered glucagon (the hormone that tells the liver to release glucose) and slowed stomach emptying. In the brain it acted on appetite-regulating areas of the hypothalamus and hindbrain, which reduced hunger and food intake; this is the basis of its use for weight management. The fatty-acid chain lets it ride on albumin and resist breakdown by the enzyme DPP-4, giving a half-life of about 13 hours.

What it has been studied for

  • Blood-glucose control in type 2 diabetes
  • Reducing heart attack, stroke and cardiovascular death in type 2 diabetes (LEADER)
  • Weight management in adults with obesity or overweight (SCALE program)
  • Weight management in children and adolescents with obesity
  • How the GLP-1 drug class was designed (liraglutide and semaglutide development)

Strength of the evidence

Approved drugLiraglutide is FDA- and EMA-approved for type 2 diabetes and for weight management, supported by large randomized trials including a cardiovascular outcome trial.

What the literature reports on safety

Trials most often reported nausea, vomiting, diarrhoea and constipation, usually early in treatment; gallbladder disease, pancreatitis, raised heart rate and low blood sugar when combined with insulin or sulfonylureas are listed risks. The US labels carry a boxed warning because liraglutide caused thyroid C-cell tumours in rodents, and it is contraindicated with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2; weight-management use is not recommended in pregnancy. It is a prescription drug; supplies sold outside licensed pharmacies are unregulated.

Key papers

  1. The Discovery and Development of Liraglutide and Semaglutide. (opens in a new tab)

    Review · Knudsen LB, Lau J · Frontiers in Endocrinology (2019) · PMID 31031702

    Described how attaching a fatty-acid chain let the GLP-1 analogue bind reversibly to albumin, extending its action while keeping its potency at the GLP-1 receptor, and how receptors in the pancreas and brain account for its effects on blood glucose and body weight.

  2. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. (opens in a new tab)

    Review · Nauck MA, Quast DR, et al. · Molecular Metabolism (2021) · PMID 33068776

    Reviewed shared mechanisms, glucose and weight effects, the absence of an intrinsic hypoglycaemia risk, and cardiovascular outcome trials across the GLP-1 agonist class, including liraglutide.

  3. Medications for Obesity: A Review. (opens in a new tab)

    Review · Gudzune KA, Kushner RF · JAMA (2024) · PMID 39037780

    Placed liraglutide among the approved obesity medications; in meta-analyses it was associated with 4.7% greater weight loss than placebo, compared with 11.4% for semaglutide and 12.4% for tirzepatide.

  4. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. (opens in a new tab)

    Randomized trial · Marso SP, Daniels GH, et al. · New England Journal of Medicine (2016) · PMID 27295427

    In 9340 people with type 2 diabetes at high cardiovascular risk (LEADER), followed for a median of 3.8 years, liraglutide lowered the combined rate of cardiovascular death, heart attack and stroke (13.0% versus 14.9%) and lowered death from any cause compared with placebo.

  5. Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial. (opens in a new tab)

    Randomized trial · Fox CK, Barrientos-Pérez M, et al. · New England Journal of Medicine (2025) · PMID 39258838

    In 82 children aged 6 to under 12 with obesity, liraglutide with lifestyle therapy reduced body-mass index more than placebo over 56 weeks (a difference of 7.4 percentage points), with more gastrointestinal side effects (80% versus 54%).

  6. Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions. (opens in a new tab)

    Review · Jalleh RJ, Rayner CK, et al. · Lancet Gastroenterology and Hepatology (2024) · PMID 39096914

    Summarized how GLP-1 agonists slow stomach emptying, noted that marked slowing may raise the risk of inhaling stomach contents during surgery or endoscopy, and proposed pre-procedure management pathways while noting a poor evidence base.

Sources checked: PubMed/PMC (E-utilities esummary on every PMID), written 2026-11-06.

No sources yet

None of the three teachers' sources we have indexed discuss Liraglutide yet. This page will fill in as sources are added.

Deeper guided audio lives on What Am I Appreciating Now (leaves this site, opens in a new tab). What Am I Appreciating Now is a separate site run by the same operator; it sells meditation and hypnosis sessions.

Disclaimer: for research purposes only

All content on this page is for research and educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any peptide or hormone protocol. You take responsibility for your own protocol.If your path includes peptides, you buy them yourself from an independent licensed provider through a member co-op; we take nothing. How independent access works.

Liraglutide — Hunter, Taylor, Bachmeyer | Reset Biology